Transapical transcatheter mitral valve-in-valve implantation was first reported in 2009 [1] and small case series have been reported [2, 3] . We present a case of transcatheter aortic valve implantation (TAVI) in the mitral position, highlighting the role of 3-dimensional echocardiography during this complex intervention in the cardiac catheter laboratory.
An 88-year-old lady, with a previous 25-mm Carpentier-Edwards 6900 Perimount pericardial mitral bioprosthesis in 2007 for severe mitral regurgitation, presented in September 2013 with shortness of breath on moderate exertion with New York Heart Association (NYHA) class 3 heart failure. Transthoracic down for repeat mitral valve surgery due to frailty. The mitral multidisciplinary team decision for transcatheter mitral valve-in-valve implantation was subsequently discussed with the patient who accepted a 10% risk of death or major adverse cardiac event. Sizing of the prosthetic annulus and leaflet area was performed pre-procedure using computed tomography (CT) ( Figure 1 ) and a plan for 26-mm device implantation was made.
and transesophageal echocardiography demonstrated good biventricular systolic function but significant transvalvular mitral prosthesis regurgitation and severe restriction of the leaflets. Left and right heart catheterization demonstrated unobstructed epicardial coronary arteries and severely elevated peak pulmonary artery systolic pressure (PASP) of 80 mm Hg. She was reviewed by the cardiothoracic surgeons and turned thetic ring (Figure 6 ). A good position was seen on fluoroscopy and 2D and 3D TOE showed only minimal paravalvular leak (Videos 4-7) . A significant increase in mitral valve area and reduction in transmitral gradient was observed ( Figures 7-8) . The patient remained hemodynamically stable throughout the procedure. The temporary wire was removed and the patient was transferred to the cardiothoracic intensive care unit and discharged on day 6 on aspirin and clopido- grel. She remained well at 6 month review with a well seated valve on transthoracic echocardiography and a reduction in estimated pulmonary artery systolic pressure to 46mmHg.
Valve-in-valve implantation, a new technology only possible with state-of-the-art imaging, is a viable treatment option for degenerative tissue bioprosthesis disease in high risk surgical patients. CT is helpful for accurate sizing of the Edwards transcatheter stented valve and detailed periprocedural examination by TOE is needed to define anatomy, guide the procedure and provides immediate assessment of potential complications.
